JP2012211150A5 - - Google Patents

Download PDF

Info

Publication number
JP2012211150A5
JP2012211150A5 JP2012128597A JP2012128597A JP2012211150A5 JP 2012211150 A5 JP2012211150 A5 JP 2012211150A5 JP 2012128597 A JP2012128597 A JP 2012128597A JP 2012128597 A JP2012128597 A JP 2012128597A JP 2012211150 A5 JP2012211150 A5 JP 2012211150A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
liquid pharmaceutical
botulinum neurotoxin
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012128597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012211150A (ja
JP5662379B2 (ja
Filing date
Publication date
Priority claimed from GB0415491A external-priority patent/GB2416122A/en
Application filed filed Critical
Publication of JP2012211150A publication Critical patent/JP2012211150A/ja
Publication of JP2012211150A5 publication Critical patent/JP2012211150A5/ja
Application granted granted Critical
Publication of JP5662379B2 publication Critical patent/JP5662379B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012128597A 2004-07-12 2012-06-06 ボツリヌス神経毒を含む医薬組成物 Expired - Lifetime JP5662379B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0415491A GB2416122A (en) 2004-07-12 2004-07-12 Botulinum neurotoxin composition
GB0415491.0 2004-07-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007520876A Division JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2012211150A JP2012211150A (ja) 2012-11-01
JP2012211150A5 true JP2012211150A5 (Direct) 2014-08-21
JP5662379B2 JP5662379B2 (ja) 2015-01-28

Family

ID=32865775

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007520876A Expired - Lifetime JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物
JP2012128597A Expired - Lifetime JP5662379B2 (ja) 2004-07-12 2012-06-06 ボツリヌス神経毒を含む医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007520876A Expired - Lifetime JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物

Country Status (19)

Country Link
US (4) US9125804B2 (Direct)
EP (4) EP3446701B1 (Direct)
JP (2) JP5301830B2 (Direct)
CN (2) CN102327602B (Direct)
AR (2) AR049978A1 (Direct)
BR (1) BRPI0513327B8 (Direct)
CA (1) CA2572915C (Direct)
DK (3) DK1817051T4 (Direct)
ES (3) ES2537312T5 (Direct)
FI (1) FI1817051T4 (Direct)
GB (1) GB2416122A (Direct)
HU (2) HUE043301T2 (Direct)
IL (1) IL180380A (Direct)
MX (1) MX2007000409A (Direct)
PL (3) PL1817051T5 (Direct)
PT (3) PT1817051E (Direct)
RU (1) RU2407541C2 (Direct)
TR (1) TR201906275T4 (Direct)
WO (1) WO2006005910A2 (Direct)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
CN101083907B (zh) 2004-03-03 2012-10-10 雷文斯治疗公司 用于局部诊断剂和治疗剂运输的组合物和方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
AU2006218431B2 (en) 2005-03-03 2012-12-06 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
BRPI0613631A8 (pt) 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2016204034B2 (en) * 2005-10-06 2017-12-21 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
KR101903920B1 (ko) 2005-12-01 2018-11-13 유니버시티 오브 메사츄세츠 로웰 보툴리눔 나노에멀젼
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
CN107080703A (zh) 2006-12-01 2017-08-22 安特里奥公司 肽纳米粒子和其用途
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
CA2688415C (en) 2007-05-31 2015-11-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
BRPI0813948B8 (pt) 2007-07-10 2021-05-25 Medy Tox Inc composição líquida farmacêutica de toxina botulínica com estabilidade melhorada
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
AU2009339292B2 (en) * 2008-12-10 2016-01-21 Allergan, Inc. Clostridial toxin pharmaceutical compositions
DK2379104T3 (en) 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US9340587B2 (en) * 2009-06-25 2016-05-17 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
EP2627318B1 (en) 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients
SG10202013124XA (en) * 2011-03-31 2021-02-25 Medy Tox Inc Lyophilized preparation of botulinum toxin
WO2013049139A1 (en) * 2011-09-28 2013-04-04 Wisconsin Alumni Research Foundation Purification, characterization, and use of clostridium botulinum neurotoxin bont/a3
JP2015534814A (ja) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド 組換えクロストリジウムボツリヌス神経毒
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
KR20210068606A (ko) 2013-03-15 2021-06-09 오프로 테라퓨틱스 인코퍼레이션 점액 점도 정상화를 위한 생성물 및 방법
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2593344C2 (ru) * 2014-03-05 2016-08-10 Михаил Григорьевич Сойхер Способ лечения бруксизма
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
WO2016102068A1 (en) * 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
CN107206175B (zh) 2015-02-03 2021-06-01 莫茨制药有限及两合公司 肉毒杆菌毒素预填充式容器
JP6955491B2 (ja) 2015-10-29 2021-10-27 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
US10874626B2 (en) 2016-04-07 2020-12-29 Nevakar Inc. Formulation for use in a method of treatment of pain
DK3679946T3 (da) 2016-05-27 2022-02-07 Ipsen Biopharm Ltd Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin
RU2651044C2 (ru) * 2016-08-22 2018-04-18 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) Способ лечения желудочковых нарушений ритма сердца (варианты)
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
SI3432916T1 (sl) 2016-09-13 2020-01-31 Allergan, Inc. Stabilizirani ne-protein klostridijski toksin sestavki
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
EP3583125B1 (en) 2017-02-16 2025-01-22 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins
CA3075414A1 (en) 2017-10-03 2019-04-11 Nevakar Inc. Acetaminophen-pregabalin combinations and methods of treating pain
WO2019113044A1 (en) * 2017-12-07 2019-06-13 Ps Therapies Ltd Topical compositions and methods of use thereof
BR112021015480A2 (pt) * 2019-02-21 2021-10-05 Merz Pharma Gmbh & Co. Kgaa Usos inovadores de neurotoxina botulínica para o tratamento contra tremor
RU2728102C1 (ru) * 2019-12-19 2020-07-28 Александр Александрович Ильин Способ лечения гипертонуса латеральной крыловидной мышцы
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
EP4265239A4 (en) * 2020-12-18 2024-11-06 ATGC Co., Ltd. PHARMACEUTICAL COMPOSITION FOR LONG-TERM STORAGE OF A LIQUID FORMULATION OF BOTULINUM TOXIN
CN119258202A (zh) * 2023-07-05 2025-01-07 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物及其应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
EP1016673B1 (en) * 1992-10-02 2006-02-01 Genetics Institute, LLC Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
WO1999037326A1 (en) 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
ES2368061T3 (es) * 2000-02-08 2011-11-14 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
AU2002320127A1 (en) * 2001-06-21 2003-01-08 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
US20030224020A1 (en) * 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
RU2206337C1 (ru) * 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
TR201708749T4 (tr) 2004-08-04 2018-03-21 Ipsen Biopharm Ltd Botuli̇num nörotoksi̇n a2 i̇çeren farmasöti̇k bi̇leşi̇m
ES2526913T3 (es) 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina 2 botulínica
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2012211150A5 (Direct)
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
PE20241346A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones que los comprenden
IL259921A (en) A new stabilizing factor for pharmaceutical proteins
PE20121517A1 (es) Compuestos lipopeptidos y metodos relacionados
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
JP2016065060A5 (Direct)
JP2012515221A5 (Direct)
JP2013543505A5 (Direct)
AR081679A1 (es) Metodos y composiciones para la administracion intratecal de heparan n-sulfatasa, envase
NZ725360A (en) Liquid pharmaceutical composition
HRP20201242T1 (hr) Tekući farmaceutski pripravak
JP2019509311A5 (Direct)
HRP20160295T1 (hr) Stabilizirana tekuća i liofilizirana formulacija adamts13
JP2013508315A5 (Direct)
RU2011122629A (ru) Водная композиция, содержащая фолликулостимулирующий гормон
BR112015008815A2 (pt) variantes do receptor iib de fc gama
JP2014516515A5 (Direct)
CU20170176A7 (es) Composición farmacéutica que comprende péptido tipo apl
CN104507495A (zh) 轮状病毒疫苗组合物及其制备方法
FI3554474T3 (fi) Mikafungiinikoostumuksia
AR086672A1 (es) Formulaciones de furina recombinante
JP2014519506A5 (Direct)
JP2018522894A5 (Direct)
CR20200240A (es) Formulación farmacéutica estable de una proteína de fusión